西罗莫司治疗系统性红斑狼疮的疗效与安全性:系统评价与荟萃分析
该研究系统检索并荟萃分析了9项研究共145例SLE患者,评估西罗莫司的疗效与安全性。在111例临床活动患者中,SLEDAI、BILAG和泼尼松剂量分别平均下降4.85、1.98和13.17 mg/天;23例活动性SLE中17例(73.9%)达到缓解,22例静止期狼疮肾炎中21例(95.5%)维持缓解。不良反应以血液学、皮肤黏膜异常和高脂血症最常见,9.28%(13/140)因副作用提前停药,多数轻微且停药后迅速恢复。
要点
- 西罗莫司可降低活动性SLE的SLEDAI、BILAG评分及泼尼松用量。
- 活动性SLE缓解率73.9%,静止期狼疮肾炎维持缓解率95.5%。
- 不良反应以血液学、皮肤黏膜异常和高脂血症为主,多数轻微。
核心结论
- 现有数据集汇总提示西罗莫司治疗SLE有前景且耐受性良好,仍需随机对照试验进一步评估其获益与风险。
研究设计与样本
- 系统检索Medline/PubMed、EMBASE、Cochrane图书馆和Scopus,纳入报告SLE患者西罗莫司疗效或安全性数据的原始病例报告、病例系列、观察性研究和临床试验,共纳入9项研究145例患者。
主要发现
- 西罗莫司暴露为245.8患者年,多数研究采用1-3 mg/天。
- 111例临床活动患者中,SLEDAI、BILAG和泼尼松剂量的合并下降分别为4.85(95%CI 3.44-6.25)、1.98(95%CI 0.23-3.74)和13.17 mg/天(95%CI 0.71-25.63)。
- 23例因活动性SLE起始西罗莫司的患者中17例(73.9%)达到缓解。
- 22例静止期狼疮肾炎患者中21例(95.5%)维持缓解。
- 血液学、皮肤黏膜异常和高脂血症是最常见的不良事件,9.28%(13/140)因副作用提前停药,多数副作用轻微且停药后迅速恢复。
关键数值与推荐
- 活动性SLE患者SLEDAI合并下降4.85(95%CI 3.44-6.25)。
- 活动性SLE患者BILAG合并下降1.98(95%CI 0.23-3.74)。
- 活动性SLE患者泼尼松剂量合并下降13.17 mg/天(95%CI 0.71-25.63)。
- 活动性SLE缓解率为73.9%(17/23),静止期狼疮肾炎维持缓解率为95.5%(21/22)。
- 因副作用提前停药比例为9.28%(13/140)。
临床怎么用
- 对于活动性SLE患者,西罗莫司可能有助于降低疾病活动度评分并减少泼尼松用量。
- 对于静止期狼疮肾炎患者,西罗莫司可能有助于维持缓解。
- 使用西罗莫司时需监测血液学异常、皮肤黏膜异常和高脂血症等不良反应。
局限性
- 纳入研究多为观察性研究或病例报告,样本量有限,缺乏随机对照试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging evidence suggested a potential therapeutic role of targeting mTOR in the treatment of SLE. But most studies were observational studies with limited sample size or case reports. OBJECTIVE: To evaluate the efficacy and safety of sirolimus in treatment of SLE by systematic review and meta-analysis. METHODS: Systematic searches of Medline/PubMed, EMBASE, the Cochrane library and Scopus were performed. Original case reports, case series, observational studies and clinical trials reporting the efficacy or safety data on SLE patients treated with sirolimus were included. A random-effects meta-analysis was performed to calculate the pooled efficacy, when possible. RESULTS: A total of 9 studies comprising 145 patients were identified. The exposure of sirolimus was 245.8 patient-years, with 1-3 mg/day adopted in majority studies. In 111 clinical active patients, the pooled decrease of SLEDAI, BILAG and prednisone dosage was 4.85 (95% CI 3.44-6.25), 1.98 (95% CI 0.23-3.74) and 13.17 mg/day (95% CI 0.71-25.63) respectively. 23 patients initiating sirolimus for active SLE yielded remission in 17 (73.9%) patients. In 22 quiescent lupus nephritis patients, 21 (95.5%) patients sustained remission. Hematological, mucocutaneous abnormalities and dyslipidemia were the most common adverse events. Early cessation due to side effects was reported in 9.28% (13/140) patients, most of the side effects were mild and recovered quickly after cessation. CONCLUSIONS: Summary of the available datasets indicated sirolimus was promising and well-tolerated in the treatment of SLE. Further randomized controlled trials evaluating the potential benefits and risk of sirolimus in SLE are warranted.
引用
- Ji L, Xie W, Zhang Z, et al. Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020. PMID: 32911286. doi:10.1016/j.semarthrit.2020.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。